Merck & Co. has established a strategic collaboration with Mayo Clinic to integrate artificial intelligence and advanced analytics into its drug discovery operations. The partnership will leverage Mayo Clinic's extensive multimodal data repositories to train, validate, and refine AI models designed to accelerate the development of new therapeutics.
The initial phase of the collaboration will focus on three therapeutic areas: inflammatory bowel disease, atopic dermatitis, and multiple sclerosis. By combining Merck's pharmaceutical expertise with Mayo Clinic's clinical data assets and analytical capabilities, the partners aim to enhance the efficiency and efficacy of drug candidate identification and validation processes.
The announcement comes as pharmaceutical companies increasingly adopt artificial intelligence to address rising drug development costs and extended timelines. However, Merck's share price declined on the announcement day, underperforming broader healthcare sector indices despite the strategic nature of the partnership.